An observational study in Solid and Hematological Malignancies and Autoimmune Diseases, sponsored by Kite, A Gilead Company. Enrolling by invitation at 91 sites in 14 countries. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 25th largest by planned enrollment of the 157 observational ones that give a count, is one of 75 that started in 2021, is one of 157 observational ones, reaches primary completion later than 267 of the 274 other live ones, and was the 618th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
823 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 278 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 75 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 660 interventional studies, 150 across the 157 observational. Of the 498 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 823 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Gilead Sciences has 4 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
87 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 87 to your calendar (.ics) → With an account.
Among the 823 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene autoleucel, INT2104, KITE-512, ACLX-001, and ACLX002 in participants of Kite-sponsored interventional studies.
The primary objectives of this study are to:
The participants who received an infusion of gene-modified cells and have not died, withdrawn consent, been withdrawn by the investigator, or been lost to follow-up at the time of transition from the completed parent study.
Inclusion Criteria:
Exclusion Criteria: none
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants who previously received axicabtagene ciloleucel (KTE-C19) in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: Axicabtagene Ciloleucel
All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: Brexucabtagene Autoleucel
All participants who previously received anitocabtagene autleucel in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: Anitocabtagene autleucel
All participants who previously received KITE-753 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: KITE-753
All participants who previously received KITE-197 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: KITE-197
All participants who previously received KITE-363 for oncology indication in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: KITE-363
All participants who previously received KITE-363 for autoimmune indication in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: KITE-363
All participants who previously received INT2104 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: INT2104
All participants who previously received KITE-512 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: KITE-512
All participants who previously received ACLX-001 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: SPRX001 · Biological: ARC-T Cells
All participants who previously received ACLX-002 in the parent study will be enrolled in this cohort for long-term follow-up.
Biological: SPRX002 · Biological: ARC-T Cells
No investigational product will be administered
Also known as: Yescarta®
No investigational product will be administered
Also known as: Tecartus™
No investigational product will be administered
Also known as: CART-ddBCMA
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
No investigational product will be administered
Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)
Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, and serious infections.
Time frame: Up to 15 years
Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)
Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, and serious infections.
Time frame: Up to 15 years
Percentage of Participants With New Malignancies
New malignancies regardless of causality includes time to development of the new malignancy, type, location, staging, and molecular mechanism (including testing for presence of the CAR transgene and (replication-competent retrovirus/replication-competent lentivirus (RCR/RCL)). Also to assess the occurrence of all related SAEs that do not fall under the umbrella of targeted events.
Time frame: Up to 15 years
Percentage of Participants Experiencing Related SAEs
Adverse events which might be possibly related to the treatment drugs.
Time frame: Up to 15 years
Height of Pediatric and Adolescent Participants
Time frame: Up to 15 years
Weight of Pediatric and Adolescent Participants
Time frame: Up to 15 years
Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale Score
The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult.
Time frame: Up to 15 years
Time to Subsequent Anticancer Therapies
Time to subsequent anticancer therapies will be assessed only per regulatory request or sponsor needs.
Time frame: Up to 15 years
Survival Status Assessment
Survival status will be assessed as the length of time from the participant's first dose date of study drug to death during the study due to any cause or last date of being alive during the study. Survival status will be assessed only per regulatory request or sponsor needs.
Time frame: Up to 15 years
Percentage of Participants With Cause of Death
Time frame: Up to 15 years
Overall Rate of Replication-competent RCR/RCL
Time frame: Up to 15 years
Percentage of Participants With Vector Integration Site(s) for RCR/RCL or Insertional Mutagenesis for Confirmed Events Related to the Cell Therapy Product
Time frame: Up to 15 years
Percentage of Participants With Status of Primary Malignant Disease
Time frame: Up to 15 years
Plan to share: No
Started Dec 2021 (actual). Primary completion is estimated for Dec 2040, 228 months after the start.
Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 228 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.